A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis

M. Ueda, R. Dunbar, A. Wolska, Tracey U. Sikora, Maria Escobar, Naomi Seliktar, Emil M Degoma, S. Derohannessian, Linda Morrell, A. McIntyre, Frances M. Burke, D. Sviridov, M. Amar, R. Shamburek, L. Freeman, R. Hegele, A. Remaley, D. Rader
{"title":"A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis","authors":"M. Ueda, R. Dunbar, A. Wolska, Tracey U. Sikora, Maria Escobar, Naomi Seliktar, Emil M Degoma, S. Derohannessian, Linda Morrell, A. McIntyre, Frances M. Burke, D. Sviridov, M. Amar, R. Shamburek, L. Freeman, R. Hegele, A. Remaley, D. Rader","doi":"10.1210/jc.2016-3903","DOIUrl":null,"url":null,"abstract":"Context\nFamilial chylomicronemia syndrome (FCS) is a rare heritable disorder associated with severe hypertriglyceridemia and recurrent pancreatitis. Lipoprotein lipase deficiency and apolipoprotein C-II deficiency are two well-characterized autosomal recessive causes of FCS, and three other genes have been described to cause FCS. Because therapeutic approaches can vary according to the underlying etiology, it is important to establish the molecular etiology of FCS.\n\n\nCase Description\nA man originally from North Africa was referred to the University of Pennsylvania Lipid Clinic for severe hypertriglyceridemia and recurrent pancreatitis, consistent with the clinical diagnosis of FCS. Molecular analyses of FCS-associated genes revealed a homozygous missense variant R72T in APOC2. Molecular modeling of the variant predicted that the apolipoprotein C-II R72T peptide has reduced lipid binding affinity. In vitro studies of the patient's plasma confirmed the lack of functional apoC-II activity. Moreover, the apoC-II protein was undetectable in the patient's plasma, quantitatively as well as qualitatively.\n\n\nConclusions\nWe identified a missense APOC2 variant causing apoC-II deficiency in a patient with severe hypertriglyceridemia and recurrent pancreatitis. Beyond dietary management and usual pharmacologic therapies, an apoC-II mimetic peptide may become an optional therapy in patients with apoC-II deficiency in the future.","PeriodicalId":22632,"journal":{"name":"The Journal of Clinical Endocrinology & Metabolism","volume":"26 1","pages":"1454–1457"},"PeriodicalIF":0.0000,"publicationDate":"2017-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"31","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Clinical Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/jc.2016-3903","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 31

Abstract

Context Familial chylomicronemia syndrome (FCS) is a rare heritable disorder associated with severe hypertriglyceridemia and recurrent pancreatitis. Lipoprotein lipase deficiency and apolipoprotein C-II deficiency are two well-characterized autosomal recessive causes of FCS, and three other genes have been described to cause FCS. Because therapeutic approaches can vary according to the underlying etiology, it is important to establish the molecular etiology of FCS. Case Description A man originally from North Africa was referred to the University of Pennsylvania Lipid Clinic for severe hypertriglyceridemia and recurrent pancreatitis, consistent with the clinical diagnosis of FCS. Molecular analyses of FCS-associated genes revealed a homozygous missense variant R72T in APOC2. Molecular modeling of the variant predicted that the apolipoprotein C-II R72T peptide has reduced lipid binding affinity. In vitro studies of the patient's plasma confirmed the lack of functional apoC-II activity. Moreover, the apoC-II protein was undetectable in the patient's plasma, quantitatively as well as qualitatively. Conclusions We identified a missense APOC2 variant causing apoC-II deficiency in a patient with severe hypertriglyceridemia and recurrent pancreatitis. Beyond dietary management and usual pharmacologic therapies, an apoC-II mimetic peptide may become an optional therapy in patients with apoC-II deficiency in the future.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一种新的APOC2错义突变导致载脂蛋白C-II缺乏伴严重甘油三酯血症和胰腺炎
家族性乳糜小铁血症综合征(FCS)是一种罕见的遗传性疾病,与严重的高甘油三酯血症和复发性胰腺炎相关。脂蛋白脂肪酶缺乏症和载脂蛋白C-II缺乏症是FCS的两种典型的常染色体隐性原因,另外三种基因也被描述为导致FCS的原因。由于治疗方法可以根据潜在的病因而变化,因此建立FCS的分子病因学非常重要。病例描述:一名来自北非的男子因严重高甘油三酯血症和复发性胰腺炎被转介到宾夕法尼亚大学脂质诊所,与FCS的临床诊断一致。fcs相关基因的分子分析显示,APOC2中存在一个纯合错义变异R72T。该变异的分子模型预测载脂蛋白C-II R72T肽具有降低的脂质结合亲和力。患者血浆的体外研究证实apoC-II缺乏功能性活性。此外,apoC-II蛋白在患者血浆中无法检测到,无论是定量还是定性。结论:我们在一例严重高甘油三酯血症和复发性胰腺炎患者中发现了一种错义APOC2变异,导致apoC-II缺乏。除了饮食管理和通常的药物治疗外,apoC-II模拟肽可能成为apoC-II缺乏症患者的可选治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Treatment Preferences in Patients with Hypothyroidism: an Analysis of Eleven Randomized Controlled Trials. Metabolomics: A Promising Tool in the Prevention, Diagnosis, and Treatment of Obesity. Association between papillary thyroid cancer and primary aldosteronism in individuals with hypertension. The changing treatment paradigm in prolactinoma - a prospective series of 100 consecutive neurosurgical cases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1